Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Acne Drug Switch Study Stirs FDA Doubts About Pregnant Women's Self-Selection

This article was originally published in The Tan Sheet

Executive Summary

The NDAC met April 15 to make recommendations on Galderma's first-in-class switch proposal for adapalene gel 0.1% indicated for treatment of acne in consumers ages 12 and older. FDA told the committee Galderma's study did not "demonstrate that pregnant or breastfeeding women could adequately self-select to use the product."

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS108276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel